Loading...
SRCL logo

Stericycle, Inc.NasdaqGS:SRCL Voorraadrapport

Marktkapitalisatie US$5.8b
Prijs aandeel
n/a
US$61.81
n.v.t.intrinsieke korting
1Y50.9%
7D1.8%
1D
Portefeuillewaarde
Bekijk

Stericycle, Inc.

NasdaqGS:SRCL Voorraadrapport

Marktkapitalisatie: US$5.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Stericycle (SRCL) Aandelenoverzicht

Stericycle, Inc. levert samen met haar dochterondernemingen gereguleerde afval- en nalevingsdiensten in de Verenigde Staten, Europa en internationaal. Meer informatie

SRCL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Stericycle, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Stericycle
Historische aandelenkoersen
Huidige aandelenkoersUS$61.98
52 Week HoogtepuntUS$61.99
52 Week LaagUS$40.47
Bèta1.11
1 maand verandering1.61%
3 maanden verandering6.29%
1 Jaar Verandering50.88%
3 jaar verandering0.75%
5 jaar verandering0.27%
Verandering sinds IPO2,580.22%

Recent nieuws en updates

Seeking Alpha Jun 04

Waste Management's Big Move Is A Win For Stericycle

Summary Waste Management announces the acquisition of Stericycle in a $7.15 billion all-cash deal, causing Stericycle shares to spike and Waste Management shares to drop. Stericycle shareholders benefit from the premium offer and can exit their position, while Waste Management's success depends on the realization of synergies and the impact on leverage. Waste Management aims to expand its environmental service offerings and gain access to Stericycle's regulated waste and compliance services, as well as its secure information destruction services. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha Jun 04

Waste Management's Big Move Is A Win For Stericycle

Summary Waste Management announces the acquisition of Stericycle in a $7.15 billion all-cash deal, causing Stericycle shares to spike and Waste Management shares to drop. Stericycle shareholders benefit from the premium offer and can exit their position, while Waste Management's success depends on the realization of synergies and the impact on leverage. Waste Management aims to expand its environmental service offerings and gain access to Stericycle's regulated waste and compliance services, as well as its secure information destruction services. Read the full article on Seeking Alpha
Seeking Alpha May 22

Stericycle: Watch Potential Revenue Recovery And Margin Improvement

Summary SRCL's Q1 2024 operating margins beat expectations, and the company's EBITDA margin is expected to improve significantly for full-year 2024. I anticipate that Stericycle's Secure Information Destruction segment can realize a turnaround due to a more favorable base for YoY comparison in 2H and the introduction of a subscription service. My Buy rating for SRCL stays intact following an assessment of its outlook and valuations. Read the full article on Seeking Alpha
Seeking Alpha Mar 03

Stericycle: Earnings Beat And Above-Expectations Guidance Reinforce My Buy Rating

Summary Stericycle's normalized EPS grew by +26% QoQ in Q4 2023, and this translated into a +14% bottom line beat. The company is anticipating that its earnings will expand strongly by +24% in this new fiscal year, which is better than what Wall Street had anticipated earlier. I stick to a Buy investment rating for Stericycle stock, as I have greater confidence in SRCL's long-term prospects after reviewing its Q4 results and 2024 guidance. Read the full article on Seeking Alpha
Seeking Alpha Aug 30

Stericycle: Muted Outlook, Fair Valuations

Summary Stericycle's revenue outlook is murky, the recovery for the secure information destruction business is still in progress, but the regulated waste and compliance segment might be affected by staffing shortages. SRCL should still record lower earnings for FY 2022 vis-a-vis FY 2021 despite delivering an EPS beat in Q2, due to higher operating and interest expenses. I continue to assign a Hold rating to Stericycle, as its valuations are reasonably fair and aligned with its full-year outlook. Elevator Pitch I rate Stericycle, Inc.'s (SRCL) stock as a Hold. I evaluated SRCL's pace of recovery from the pandemic and its capital allocation plans in an earlier October 22, 2021 article for the stock. I focus on the near-term expectations for Stericycle in this update. My analysis leads me to the conclusion that the consensus earnings forecasts implying a mid-single digit percentage decline for SRCL in FY 2022 are realistic, and Stericycle's current valuations seem to be fair taking into account the full-year outlook. As such, I maintain a Hold rating for SRCL. Revisions To Consensus Estimates The recent changes to the sell-side's consensus bottom line forecasts for Stericycle provide an indication of what the market expects of SRCL's future performance. The consensus Q3 2022 normalized earnings per share or EPS for SRCL has been revised upwards by a substantial +11% in the past one month. It is reasonable to assume that the Wall Street analysts had raised their third-quarter bottom line projections for the company in response to Stericycle's +9% EPS beat for Q2 2022. It is worthy of note that SRCL has had earnings misses for the prior four quarters between Q2 2021 and Q1 2022. But the full-year fiscal 2022 consensus numbers tell a different story. In the last one month, the market's consensus FY 2022 normalized EPS estimate ($2.06) for Stericycle has in fact been reduced slightly by -0.5%, notwithstanding SRCL's second-quarter earnings beat. Moreover, four of the eight analysts covering SRCL's shares actually lowered their EPS estimates for the company in the past month. The analysts' less than favorable view of Stericycle's full-year FY 2022 outlook might be linked to the company's most recently updated management guidance. At its Q2 2022 earnings call in early-August 2022, SRCL increased the mid-point of its FY 2022 revenue growth guidance from +4% to +5%, but it lowered the mid-point of its full-year EPS guidance from $2.15 to $2.075 (implying a -5% decline as compared to 2021 EPS of $2.19). In the rest of the article, I will assess the growth prospects of its two key business segment and the company's overall profitability. This will help to explain why company management and analysts are of the opinion that Stericycle's bottom line for FY 2022 will still contract despite above-expectations Q2 2022 earnings. Secure Information Destruction Business Performed Well in Q2 Organic revenue for Stericycle's secure information destruction business, adjusted to exclude inorganic transactions and foreign exchange effects, expanded by an impressive +12.2% YoY for the second quarter of 2022. The expectations for SRCL's secure information destruction segment weren't high, as this business faces structural challenges relating to reduced paper usage in an increasingly digitalized world. However, the company's business secure information destruction business has witnessed a meaningful recovery in Q2 2022, as pandemic restrictions are eased and an increasing number of workers return to offices. More critically, the current recovery for the secure information destruction segment still has legs to run. Stericycle highlighted at its second-quarter results briefing that "I don't think the industry has settled yet in terms of everybody being back to what is the new normal." In other words, SRCL is implying that there could be a further acceleration in the pace of people going back to offices in time to come, and this will be positive for the secure information destruction business' near-term outlook. Disappointing Performance For Regulated Waste And Compliance Services Segment In contrast with the double-digit top line growth for the secure information destruction segment in the recent quarter, Stericycle's other segment, the regulated waste and compliance services business disappointed investors with its Q2 2022 results. Specifically, the regulated waste and compliance services segment saw a very modest +1.8% YoY increase in its second-quarter organic revenue. Notably, SRCL mentioned at its Q2 2022 earnings briefing that "most of the growth" for the company's regulated waste and compliance services segment for the most recent quarter "was due to pricing." This suggests that volumes for this business was probably flattish on a YoY basis in the second quarter of this year. There are two key factors that explain why the regulated waste and compliance services business' volumes haven't grown in a meaningful way in the recent quarter. Firstly, there was a decline in COVID-19 testing and vaccinations in Q2, as COVID-19 transitions gradually into an endemic state. Secondly, the labor crunch has also affected the healthcare industry, which means that it is tough for the number of elective surgeries to return to similar levels seen before the pandemic anytime soon. Future Profitability Hurt By Operating Cost Pressures And Higher Interest Rates As discussed in an earlier section of the article, Stericycle cut its full-year FY 2022 bottom line guidance after it reported its Q2 2022 earnings. SRCL attributed this change to "higher cash operating and interest expenses" at its most recent quarterly investor call.
Seeking Alpha Aug 04

Stericycle Q2 2022 Earnings Preview

Stericycle (NASDAQ:SRCL) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $0.44 (-34.3% Y/Y) and the consensus Revenue Estimate is $678.27M (+0.8% Y/Y). Over the last 2 years, SRCL has beaten EPS estimates 38% of the time and has beaten revenue estimates 50% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 2 upward revisions and 1 downward.
Seeking Alpha Jun 03

Stericycle: The Risks Outweigh The Reward

Stericycle seems to be in a continued state of decline, even though the pandemic is largely over. If shares were cheap enough, the company might be worth the risk, but that isn't the case either. Add in regulatory risks moving forward, and it's not worth the risk playing this name right now.
Seeking Alpha Oct 22

Stericycle: A Neutral View

I am negative on SRCL's recovery prospects in the short term, as there has been a delay in the return of workers back to office. But I have a favorable opinion of Stericycle's capital allocation initiatives in relation to debt reduction and business or asset sales. Stericycle currently trades at consensus forward FY 2021 and FY 2022 normalized P/E multiples of 26.9 times and 25.2 times, respectively, and this seems expensive.
Seeking Alpha Aug 08

Stericycle: A Successful Turnaround Is Likely

Revenues declined in 2018, 2019, and 2020 as the company is divesting some businesses. Long-term debt has dramatically declined in recent quarters. The company is highly profitable. Shares are down by ~55% from all-time highs in 2015. This is a turnaround play worth the risk at this price.

Rendement voor aandeelhouders

SRCLUS Commercial ServicesUS Markt
7D1.8%1.2%1.1%
1Y50.9%-14.8%28.7%

Rendement versus industrie: SRCL overtrof de US Commercial Services industrie, die het afgelopen jaar een rendement -14.8 % opleverde.

Rendement versus markt: SRCL overtrof de US markt, die het afgelopen jaar een rendement opleverde van 28.7 %.

Prijsvolatiliteit

Is SRCL's price volatile compared to industry and market?
SRCL volatility
SRCL Average Weekly Movement1.4%
Commercial Services Industry Average Movement7.4%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Stabiele aandelenkoers: SRCL heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 1% ) van SRCL is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
198913,298Cindy Millerwww.stericycle.com

Stericycle, Inc. biedt samen met haar dochterondernemingen gereguleerde afval- en nalevingsdiensten aan in de Verenigde Staten, Europa en internationaal. Het bedrijf biedt gereguleerde afval- en nalevingsdiensten aan, waaronder gereguleerd medisch afval, beheer en verwijdering van scherp afval, beheer en verwijdering van farmaceutisch afval, afval en verwijdering van chemotherapie, verwijdering van gereguleerde stoffen, gevaarlijk afval uit de gezondheidszorg en geïntegreerde afvalstroomoplossingen; speciale diensten, zoals MedDrop medicijninzamelingskiosken, veilige gemeenschapsoplossingen, SafeDrop sharps mailback-oplossingen en luchthaven- en maritieme afvaldiensten; medische voorraaddiensten, waaronder scherp- en wegwerpcontainers voor biologisch gevaarlijk afval, benodigdheden voor infectiebeheersing en seal&send medicatiemailback; en nalevingsoplossingen waaronder Steri-Safe nalevingsoplossingen. Het bedrijf biedt ook veilige informatievernietiging, waaronder vernietiging van documenten en harde schijven onder de merknaam Shred-it.

Stericycle, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Stericycle zich tot de beurswaarde?
SRCL fundamentele statistieken
MarktkapitalisatieUS$5.75b
Inkomsten(TTM)US$20.20m
Inkomsten(TTM)US$2.63b
284.9x
Koers/Winstverhouding
2.2x
P/S-verhouding

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SRCL resultatenrekening (TTM)
InkomstenUS$2.63b
Kosten van inkomstenUS$1.63b
BrutowinstUS$1.00b
Overige uitgavenUS$980.10m
InkomstenUS$20.20m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)0.22
Brutomarge38.08%
Nettowinstmarge0.77%
Schuld/Eigen Vermogen Verhouding53.1%

Hoe presteerde SRCL op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2024/11/04 04:14
Aandelenkoers aan het einde van de dag2024/11/01 00:00
Inkomsten2024/09/30
Jaarlijkse inkomsten2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Stericycle, Inc. wordt gevolgd door 21 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Gary BisbeeBarclays
Alexander ParisBarrington Research Associates, Inc.
Kevin SteinkeBarrington Research Associates, Inc.